Heparegenix GMBH
USPTO PatentsView assignee record - 5 granted patents across 3 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).
The verdict
According to USPTO PatentsView, Heparegenix ranks #47,395 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 3 technology areas.
- #47,395
- of 49,997 US assignees by volume
- Top 35%
- by Innovation Score (40.7/100)
- 14.0
- avg claims per patent
USPTO PatentsView assignee plate
Corpus R47395 · Foreign Corporation #47,395 · 5 grants
GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH
- GRANTS-MICRO 5 grants
- BOTTOM-DECILE #47,395/49,997
- PHOTO-FINISH Helmer
- CPC-NARROW C07D · 3 areas
- INNOV-PAR 40.7/100
- CLAIMS-RICH 14.0 claims/avg
- TYPE-FRNCORP Foreign Corp
- SPAN-YRS 2021–2025 · 5y
- BOOK-RICH 9/10 fields
Nearest grant-volume peer: Helmer, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Heparegenix’s 40.7 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Heparegenix
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Heparegenix · this assignee
Heparegenix · this assignee
41 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Heparegenix's Innovation Score is 40.7/100 (top 35% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Heparegenix?
Each dot is one of Heparegenix’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Heparegenix’s own 14.0 claims/patent is ABOVE the 10.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Heparegenix's grants concentrate
Heparegenix GMBH is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2024 (2 grants) versus a trough of 1 in 2021. By volume, Heparegenix sits between Helmer, Inc. and Hexagon Ragasco AS.
Heparegenix's three-year grant acceleration
Heparegenix GMBH shows 3 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Heparegenix's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Helmer
Helmer, Inc.
5 patents
- Hemcon Medical
Hemcon Medical Technologies, Inc.
5 patents
- HEN Nozzles
HEN Nozzles Inc.
5 patents
- Henry S Owen
Henry S. Owen LLC
5 patents
- Hephzibah
Hephzibah Co., Ltd.
5 patents
- Here Data Technol…
Here Data Technology
5 patents
- Hexacath
Hexacath
5 patents
- Hexagon Ragasco AS
Hexagon Ragasco AS
5 patents
- Heparegenix ◀
Heparegenix GMBH
5 patents
What this shows Heparegenix holds 5 patents at rank #47,346, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Heparegenix
By rank, the assignees closest to #47,346 in granted patent volume.
- Helmer, Inc. #47,342 · 5 patents
- Hemcon Medical Technologies, Inc. #47,343 · 5 patents
- HEN Nozzles Inc. #47,344 · 5 patents
- Henry S. Owen LLC #47,345 · 5 patents
- Hephzibah Co., Ltd. #47,347 · 5 patents
- Here Data Technology #47,348 · 5 patents
- Hexacath #47,349 · 5 patents
- Hexagon Ragasco AS #47,350 · 5 patents
Leaders in C07D (Heterocyclic Compounds)
Other assignees with the most granted patents in Heparegenix's primary technology class.
Heparegenix's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
41 Top 35% higher than 65% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2021 | 1 | 20.0% |
| 2023 | 1 | 20.0% |
| 2024 | 2 | 40.0% |
| 2025partial year | 1 | 20.0% |
Which technologies does Heparegenix GMBH patent most?
Top 3 of 3 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Heparegenix GMBH's patent record in context - here's where to go next.
- Heparegenix GMBH's lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
- Ranked #47,395 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Heparegenix GMBH against Helmer, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 40.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.